Concepts (127)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Spectroscopy | 6 | 2014 | 624 | 0.970 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2005 | 494 | 0.400 |
Why?
|
| Capillary Permeability | 1 | 2006 | 114 | 0.270 |
Why?
|
| Benzodiazepines | 1 | 2006 | 170 | 0.260 |
Why?
|
| Acrylamides | 1 | 2005 | 53 | 0.260 |
Why?
|
| Lactates | 1 | 2004 | 112 | 0.250 |
Why?
|
| Disease Progression | 2 | 2014 | 6682 | 0.230 |
Why?
|
| Glioblastoma | 1 | 2014 | 1797 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2014 | 7702 | 0.200 |
Why?
|
| Electrons | 1 | 2022 | 168 | 0.190 |
Why?
|
| Piperidines | 1 | 2005 | 1035 | 0.180 |
Why?
|
| Particle Accelerators | 2 | 2022 | 352 | 0.180 |
Why?
|
| Neovascularization, Pathologic | 1 | 2006 | 1547 | 0.170 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2006 | 1248 | 0.170 |
Why?
|
| Motion | 1 | 2018 | 193 | 0.150 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 4849 | 0.150 |
Why?
|
| Colonic Neoplasms | 1 | 2004 | 1390 | 0.140 |
Why?
|
| Radiotherapy Dosage | 4 | 2022 | 3842 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 10035 | 0.140 |
Why?
|
| Phantoms, Imaging | 5 | 2022 | 1271 | 0.140 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2022 | 2370 | 0.140 |
Why?
|
| Choline | 2 | 2014 | 76 | 0.130 |
Why?
|
| Brachytherapy | 2 | 2013 | 977 | 0.130 |
Why?
|
| Mice, Inbred C3H | 2 | 2005 | 385 | 0.120 |
Why?
|
| Matched-Pair Analysis | 1 | 2014 | 103 | 0.120 |
Why?
|
| Titanium | 2 | 2013 | 61 | 0.120 |
Why?
|
| Contrast Media | 2 | 2014 | 1472 | 0.120 |
Why?
|
| Aspartic Acid | 1 | 2014 | 126 | 0.120 |
Why?
|
| Gadolinium | 1 | 2014 | 164 | 0.110 |
Why?
|
| Fiducial Markers | 1 | 2013 | 96 | 0.110 |
Why?
|
| Dacarbazine | 1 | 2014 | 485 | 0.100 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2013 | 96 | 0.100 |
Why?
|
| Breast | 1 | 2018 | 1344 | 0.100 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2014 | 925 | 0.100 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2014 | 588 | 0.100 |
Why?
|
| Apoptosis | 1 | 2005 | 7591 | 0.090 |
Why?
|
| Contusions | 1 | 2007 | 18 | 0.080 |
Why?
|
| Artifacts | 1 | 2010 | 532 | 0.080 |
Why?
|
| Lung | 1 | 2018 | 3151 | 0.070 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2018 | 2104 | 0.070 |
Why?
|
| Cordotomy | 1 | 2007 | 46 | 0.070 |
Why?
|
| Time Factors | 2 | 2014 | 12926 | 0.070 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2006 | 157 | 0.070 |
Why?
|
| Gadolinium DTPA | 1 | 2006 | 172 | 0.070 |
Why?
|
| Guanine Nucleotides | 1 | 2005 | 23 | 0.070 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 4988 | 0.070 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2005 | 20 | 0.070 |
Why?
|
| Pentosyltransferases | 1 | 2005 | 25 | 0.070 |
Why?
|
| Annexin A5 | 1 | 2005 | 72 | 0.070 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 1946 | 0.070 |
Why?
|
| Intracellular Membranes | 1 | 2005 | 108 | 0.060 |
Why?
|
| NAD | 1 | 2005 | 89 | 0.060 |
Why?
|
| NADP | 1 | 2005 | 96 | 0.060 |
Why?
|
| Prostatitis | 1 | 2004 | 18 | 0.060 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2006 | 566 | 0.060 |
Why?
|
| Phospholipids | 1 | 2005 | 177 | 0.060 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2005 | 585 | 0.060 |
Why?
|
| Spinal Cord Injuries | 1 | 2007 | 374 | 0.060 |
Why?
|
| Genital Neoplasms, Female | 1 | 2010 | 735 | 0.060 |
Why?
|
| Membrane Potentials | 1 | 2005 | 424 | 0.060 |
Why?
|
| Recovery of Function | 1 | 2007 | 703 | 0.060 |
Why?
|
| Biomarkers, Tumor | 2 | 2014 | 10331 | 0.060 |
Why?
|
| Kinetics | 1 | 2006 | 2049 | 0.060 |
Why?
|
| Mitosis | 1 | 2005 | 615 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2014 | 10001 | 0.050 |
Why?
|
| Glycolysis | 1 | 2005 | 519 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 2173 | 0.050 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 1519 | 0.050 |
Why?
|
| Prostatic Neoplasms | 4 | 2013 | 5767 | 0.050 |
Why?
|
| Prostatectomy | 1 | 2005 | 962 | 0.050 |
Why?
|
| Mice | 3 | 2006 | 34495 | 0.050 |
Why?
|
| Cell Cycle | 1 | 2005 | 2084 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 14889 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2006 | 4307 | 0.040 |
Why?
|
| Protein Binding | 1 | 2005 | 3438 | 0.040 |
Why?
|
| Mitochondria | 1 | 2005 | 1282 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2006 | 3821 | 0.040 |
Why?
|
| Animals | 4 | 2007 | 59536 | 0.040 |
Why?
|
| Male | 7 | 2018 | 123000 | 0.040 |
Why?
|
| Prostate | 2 | 2018 | 1088 | 0.040 |
Why?
|
| Head | 1 | 2018 | 249 | 0.040 |
Why?
|
| Radiometry | 1 | 2022 | 980 | 0.040 |
Why?
|
| Pelvis | 1 | 2018 | 362 | 0.030 |
Why?
|
| Humans | 11 | 2022 | 261506 | 0.030 |
Why?
|
| Respiration | 1 | 2018 | 447 | 0.030 |
Why?
|
| Neck | 1 | 2018 | 383 | 0.030 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2018 | 304 | 0.030 |
Why?
|
| Female | 5 | 2014 | 141928 | 0.030 |
Why?
|
| Iothalamate Meglumine | 1 | 2013 | 3 | 0.030 |
Why?
|
| Copper Sulfate | 1 | 2013 | 4 | 0.030 |
Why?
|
| Sepharose | 1 | 2013 | 32 | 0.030 |
Why?
|
| Cobalt | 1 | 2013 | 55 | 0.030 |
Why?
|
| Fish Oils | 1 | 2013 | 88 | 0.030 |
Why?
|
| Vitamin E | 1 | 2013 | 136 | 0.030 |
Why?
|
| Sodium Chloride | 1 | 2013 | 156 | 0.030 |
Why?
|
| Catheters | 1 | 2013 | 126 | 0.030 |
Why?
|
| Aged | 3 | 2014 | 70117 | 0.030 |
Why?
|
| Middle Aged | 4 | 2014 | 86204 | 0.030 |
Why?
|
| Uncertainty | 1 | 2013 | 320 | 0.020 |
Why?
|
| Adult | 2 | 2014 | 77950 | 0.020 |
Why?
|
| Quality Control | 1 | 2010 | 457 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2006 | 5319 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 2292 | 0.020 |
Why?
|
| Physical Conditioning, Animal | 1 | 2007 | 112 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2005 | 4971 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2013 | 7551 | 0.020 |
Why?
|
| Neoplasms | 1 | 2011 | 15193 | 0.020 |
Why?
|
| Brain | 1 | 2018 | 4113 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 1648 | 0.010 |
Why?
|
| Phosphocreatine | 1 | 2003 | 17 | 0.010 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2005 | 209 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2006 | 11538 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2004 | 355 | 0.010 |
Why?
|
| Creatine | 1 | 2003 | 61 | 0.010 |
Why?
|
| Citric Acid | 1 | 2003 | 54 | 0.010 |
Why?
|
| Motor Activity | 1 | 2007 | 693 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2007 | 2063 | 0.010 |
Why?
|
| Acute Disease | 1 | 2007 | 2422 | 0.010 |
Why?
|
| Protons | 1 | 2005 | 473 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2013 | 1833 | 0.010 |
Why?
|
| ROC Curve | 1 | 2005 | 1183 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2004 | 1819 | 0.010 |
Why?
|
| Rats | 1 | 2007 | 6086 | 0.010 |
Why?
|
| Biopsy | 1 | 2005 | 3443 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 4892 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 8865 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2004 | 37905 | 0.010 |
Why?
|